Management of Acute Viral Hepatitis in Inpatient Setting
For most cases of acute viral hepatitis, supportive care is the mainstay of inpatient management, with antiviral therapy reserved only for acute hepatitis B with impaired synthetic liver function (INR >1.5) and acute hepatitis C where immediate treatment is now recommended.
Acute Hepatitis B Management
When NOT to Treat
- Do not initiate antiviral therapy for uncomplicated acute hepatitis B - spontaneous HBsAg clearance occurs in >95% of adult cases 1
- A randomized controlled trial showed no benefit of lamivudine over placebo in standard acute hepatitis B 1
When TO Treat
Initiate nucleoside analogs immediately if synthetic liver function is impaired (prothrombin time >50% or INR >1.5) and coordinate with a transplant center 1
Dosing for Acute Hepatitis B with Liver Dysfunction:
- Tenofovir (TDF or TAF) - preferred agent 1
- TDF: 300 mg orally once daily
- TAF: 25 mg orally once daily
- Alternative: Entecavir 0.5 mg orally once daily (but switch to tenofovir if pregnancy is a consideration) 1
The evidence supporting treatment in severe cases comes from an Asian study showing reduced mortality with lamivudine in 80 patients with impaired coagulation 1, though a European study could not demonstrate clear survival benefit in less severe cases 1.
Acute Hepatitis C Management
Immediate initiation of direct-acting antivirals is recommended at diagnosis - only 25% of acute hepatitis C cases resolve spontaneously 2. This represents a paradigm shift from older approaches that delayed treatment.
Dosing for Acute Hepatitis C:
- Use standard chronic hepatitis C regimens based on genotype
- Duration: typically 8-12 weeks depending on specific DAA regimen and genotype
- Historical data showed pegylated interferon monotherapy for 6 months achieved >80% sustained response 3, but modern DAAs are far superior
Acute Hepatitis A and E Management
Supportive care only - no virus-specific treatment has proven effective 4
- Both are self-limited in immunocompetent hosts
- Critical exception: Hepatitis E in pregnant women (especially third trimester) has higher mortality and requires intensive monitoring 4
Herpes Simplex Virus Hepatitis
Immediate acyclovir 10 mg/kg IV every 8 hours for suspected or documented HSV hepatitis 4
- Consider in immunosuppressed patients, pregnant women (third trimester), or healthy individuals with acute liver failure
- Skin lesions present in only 50% of cases
- Immediately list for liver transplantation 4
General Supportive Care Measures
Monitoring Parameters
- Daily: Mental status, coagulation profile (INR/PT), bilirubin, transaminases
- Watch for fulminant hepatic failure: Any alteration in mental status requires ICU-level care
Specific Interventions
- IV hydration if unable to maintain oral intake due to nausea/vomiting 5
- High-calorie diet when tolerated 5
- Strict avoidance of hepatotoxic medications and alcohol 5
- Bedrest only if severely symptomatic 5
Transplant Considerations
Coordinate with transplant center for:
- Acute hepatitis B with INR >1.5 1
- Any acute viral hepatitis with signs of fulminant failure 4
- Wilson disease presenting as acute liver failure (bilirubin:alkaline phosphatase ratio >2.0) 4
Critical Pitfalls to Avoid
Do not routinely treat uncomplicated acute hepatitis B - the 2025 EASL guidelines strongly recommend against this given >95% spontaneous clearance 1
Do not delay treatment in acute hepatitis C - modern practice favors immediate DAA initiation rather than the historical "watch and wait" approach 2
Do not miss HSV hepatitis - high index of suspicion in immunosuppressed or pregnant patients even without skin lesions; immediate acyclovir is critical 4
Do not use penicillamine for Wilson disease in acute liver failure - risk of hypersensitivity; use albumin dialysis, hemofiltration, or plasmapheresis instead 4